Bristol-Myers Squibb Company Ce (CELG-RI) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
CELG-RI's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
CELG-RI Revenue Analysis (2013–2024)
As of March 2, 2026, Bristol-Myers Squibb Company Ce (CELG-RI) generated trailing twelve-month (TTM) revenue of $48.03 billion, reflecting modest growth of +2.8% year-over-year. The most recent quarter (Q3 2025) recorded $12.22 billion in revenue, down 0.4% sequentially.
Looking at the longer-term picture, CELG-RI's 5-year compound annual growth rate (CAGR) stands at +13.1%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $48.30 billion in 2024, representing a new all-time high.
Revenue diversification analysis shows CELG-RI's business is primarily driven by Eliquis (28%), Opdivo (19%), and Revlimid (12%).
When compared to Healthcare sector peers including LLY (+45.4% YoY), JNJ (+3.7% YoY), and AZN (+8.6% YoY), CELG-RI has underperformed the peer group in terms of revenue growth. Compare CELG-RI vs LLY →
Peer Comparison
Compare CELG-RI's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CELG-RICurrent | $48.0B | +2.8% | +13.1% | 20.0% | |
| LLY | $45.0B | +45.4% | +15.1% | 38.9% | |
| JNJ | $88.8B | +3.7% | +1.6% | 24.9% | |
| AZN | $58.7B | +8.6% | +17.2% | 23.4% | |
| BMY | $48.3B | +1.3% | +13.1% | 20.0% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $48.30B | +7.3% | $27.43B | 56.8% | $9.66B | 20.0% |
| 2023 | $45.01B | -2.5% | $34.31B | 76.2% | $8.20B | 18.2% |
| 2022 | $46.16B | -0.5% | $36.02B | 78.0% | $9.10B | 19.7% |
| 2021 | $46.38B | +9.1% | $36.45B | 78.6% | $8.54B | 18.4% |
| 2020 | $42.52B | +62.6% | $30.75B | 72.3% | $2.18B | 5.1% |
| 2019 | $26.14B | +15.9% | $18.07B | 69.1% | $5.91B | 22.6% |
| 2018 | $22.56B | +8.6% | $16.01B | 71.0% | $5.12B | 22.7% |
| 2017 | $20.78B | +6.9% | $14.71B | 70.8% | $3.45B | 16.6% |
| 2016 | $19.43B | +17.3% | $14.48B | 74.5% | $4.54B | 23.4% |
| 2015 | $16.56B | +4.3% | $12.65B | 76.4% | $1.73B | 10.4% |
See CELG-RI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CELG-RI Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CELG-RI vs AGIO
See how CELG-RI stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CELG-RI's revenue growth accelerating or slowing?
CELG-RI revenue growth slowed to +2.8%, below the 5-year CAGR of +13.1%. TTM revenue is $48.0B. The deceleration marks a shift from historical growth rates.
What is CELG-RI's long-term revenue growth rate?
Bristol-Myers Squibb Company Ce's 5-year revenue CAGR of +13.1% reflects the variable expansion pattern. Current YoY growth of +2.8% is near this long-term average.
How is CELG-RI's revenue distributed by segment?
CELG-RI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.